Walleye Capital
EBS icon

Walleye Capital’s Emergent Biosolutions EBS Stock Holding History

Walleye Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,800
Closed -$220K – 4538
2025
Q4 		$220K Sell
17,800
-900
-5% -$9.64K ﹤0.01% 3494
2025
Q3 		$165K Sell
18,700
-6,800
-27% -$52.9K ﹤0.01% 3439
2025
Q2 		$163K Buy
25,500
+8,700
+52% +$49.8K ﹤0.01% 3511
2025
Q1 		$81.6K Sell
16,800
-11,600
-41% -$96K ﹤0.01% 3693
2024
Q4 		$272K Buy
28,400
+20,900
+279% +$192K ﹤0.01% 3510
2024
Q3 		$62.6K Buy
+7,500
New +$68.2K ﹤0.01% 4566
2024
Q1 		– Sell
-100
Closed -$240 – 5509
2023
Q4 		$240 Sell
100
-5,300
-98% -$12.5K ﹤0.01% 4862
2023
Q3 		$18.4K Sell
5,400
-4,100
-43% -$22.7K ﹤0.01% 4396
2023
Q2 		$69.8K Buy
9,500
+7,300
+332% +$67.7K ﹤0.01% 3547
2023
Q1 		$22.8K Sell
2,200
-6,200
-74% -$74.9K ﹤0.01% 3375
2022
Q4 		$99.2K Sell
8,400
-11,800
-58% -$183K ﹤0.01% 2367
2022
Q3 		$424K Buy
+20,200
New +$562K 0.01% 1579

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Walleye Capital's EBS Position: Q1 2026 in Review

Walleye Capital sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 4 shares — an estimated $49 sold.

Walleye Capital first reported a position in EBS in Q3 2018 and held it in 16 quarters. The position peaked at $1.36M in Q2 2023. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Walleye Capital reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 4 Emergent Biosolutions shares in Q1 2026, an estimated $49.
  • Walleye Capital first reported a position in Emergent Biosolutions in Q3 2018 and held it in 16 quarters.
  • Walleye Capital's Emergent Biosolutions position peaked at $1.36M in Q2 2023.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.